HSPA9 and neoplasm: In addition to the classic role of mortalin in the inactivation of p53, it also improves cancer cell survival and enhances tumor progression (especially in drug-resistant tumors) through other methods, such as synergistic effects with human telomerase reverse transcriptase and heterogeneous nuclear ribonucleoprotein K (17).